SL Science Holding Ltd
SLBT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SLBT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SLBT
SL Science Holding Ltd (SLBT) is a clinical-stage biotechnology company focused on developing γδ T cell therapies for pancreatic and brain cancers, with legacy exosome cosmetic and plant supplement businesses.
Key risk: Limited cash runway
Market Cap
$1.51B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2025.
SL Science Holding Ltd (SLBT) is a clinical-stage biotechnology company focused on developing γδ T cell therapies for pancreatic and brain cancers, with legacy exosome cosmetic and plant supplement businesses.
- SL Bio has developed a proprietary ex-vivo expansion and activation process for γδ T cells derived from PBMCs, with early-stage in-vitro cytotoxicity and in-vivo efficacy data [sec · filed 2026-06-18].
- The company plans to seek development and commercialization partnerships with global pharmaceutical companies following early clinical validation (e.g., late Phase I/early Phase II) [sec · filed 2026-06-18].
- As of December 31, 2025, the Group had approximately $1.3 million in cash [sec · filed 2026-06-18].
- The company intends to gradually phase out its legacy exosome cosmetic and plant supplement businesses to focus on immune cell therapy [sec · filed 2026-06-18].
- SL Bio faces competition from well-financed biopharma companies and is working to distinguish itself through advancements [sec · filed 2026-06-18].
What works
- The global pancreatic cancer treatment market is projected to reach $10.69 billion by 2032, and the brain tumor treatment market is anticipated to rise to $4.42 billion by 2032, providing significant growth potential for SL Bio's solutions [sec · filed 2026-06-18].
- SL Bio has a founder-led management team with experience in new drug development, medical-grade health product development, and financial management [sec · filed 2026-06-18].
- The company has an extensive suite of solutions ranging from human-derived immune cell products for brain and pancreatic cancers to milk-derived exosome skin care and plant extract haircare products [sec · filed 2026-06-18].
What to weigh
- No formal GLP-compliant in-vivo toxicity studies have been completed to date for the γδ T cell platform [sec · filed 2026-06-18].
- As of December 31, 2025, the Group had only approximately $1.3 million in cash, indicating limited liquidity [sec · filed 2026-06-18].
- The company may need to raise additional funds through equity or debt, which could dilute existing shareholders or impose restrictive covenants [sec · filed 2026-06-18].
- The consummation of the business combination with HSPT is subject to numerous conditions, and there can be no assurances that such conditions will be satisfied [sec · filed 2026-06-18].
From the filings
Quoted directly from source documents.
The company has not completed formal GLP-compliant in-vivo toxicity studies for its γδ T cell platform.
“no formal GLP-compliant in-vivo toxicity studies have been completed to date for this platform”
SEC filings · June 18, 2026
The company plans to seek partnerships after early clinical validation.
“The Company plans to seek development and commercialization partnerships with global pharmaceutical companies following early clinical validation (e.g., late Phase I/early Phase II)”
SEC filings · June 18, 2026
The company had approximately $1.3 million in cash as of December 31, 2025.
“As of December 31, 2025, the Group had approximately $1.3 mil”
SEC filings · June 18, 2026
The company intends to phase out legacy non-core businesses.
“the Company intends to gradually phase out its legacy exosome cosmetic and plant supplement businesses”
SEC filings · June 18, 2026
Risks & what to watch (4)›
Key risks
- Limited cash runway — Only ~$1.3M cash as of Dec 2025, may need additional financing [sec · filed 2026-06-18]
- No GLP toxicity studies completed — γδ T cell platform lacks formal GLP-compliant in-vivo toxicity data [sec · filed 2026-06-18]
- Business combination conditions — Merger with HSPT subject to numerous conditions, no assurance of completion [sec · filed 2026-06-18]
- Competition from well-financed firms — Faces competition from well-financed biopharma companies [sec · filed 2026-06-18]
What to watch
- Completion of the business combination with HSPT and Nasdaq listing [sec · filed 2026-06-18]
- Progress toward GLP-compliant toxicity studies and IND filing for γδ T cell therapy [sec · filed 2026-06-18]
- Ability to secure development and commercialization partnerships after early clinical validation [sec · filed 2026-06-18]
- Cash position and any additional financing activities [sec · filed 2026-06-18]
Sources: Competitor trials · SEC filings · Generated August 28, 2026 · How we verify sources →
Run SL Science Holding Ltd through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available SL Science Holding Ltd facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Frequently asked questions
What is the AI investment thesis for SL Science Holding Ltd?
SL Science Holding Ltd (SLBT) is a clinical-stage biotechnology company focused on developing γδ T cell therapies for pancreatic and brain cancers, with legacy exosome cosmetic and plant supplement businesses.
Who is the CEO of SL Science Holding Ltd?
Mr. Ching-Dong Wang is the chief executive officer of SL Science Holding Ltd (SLBT).
Where is SL Science Holding Ltd headquartered?
SL Science Holding Ltd (SLBT) is headquartered in Taipei, Taiwan.
What therapeutic areas does SL Science Holding Ltd focus on?
SL Science Holding Ltd develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.